PDCD1 and breast cancer: Since the advantage of blocking PD-1 over conventional is limited to a small number of patients with breast cancer,45,46 it would be worth validating the association between PI composition and immune checkpoint pathway using a second set of tumour samples, ideally acquired from patients treated with immune checkpoint inhibition.